Alderman MH, Madhavan S., Ooi WL, Cohen H., Sealey JE, Laragh JHAssociation of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med1991;324(16):1098-104.
2.
Brunner HR, Laragh JH, Baer L. et al. Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med1972; 286(9):441-9.
3.
Pitt B., Poole-Wilson PA, Segal R. et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet2000; 335(9215): 1582-7.
4.
Vaughan DE, Rouleau JL, Ridker PM, Arnold JM, Menapace FJ, Pfeffer MAEffects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators. Circulation1997; 96(2):442-7.
5.
Pitt B., Segal R., Martinez FA et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) . Lancet1997; 349(9054):747-52.
6.
Vaughan DEFibrinolytic balance, the renin-angiotensin system and atherosclerotic disease . Eur Heart J1998; 19 Suppl G:G9-12.
7.
Hamsten A., Wiman B., de Faire U., Blomback M.Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med1985; 313(25):1557-63.
8.
Jansson JH, Boman K., Nilsson TKEnalapril-related changes in the fibrinolytic system in survivors of myocardial infarction. Eur J Clin Pharmacol1993; 44(5):485-8.
9.
Hamsten A., de Faire U., Walldius G. et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet1987; 2(8549):3-9.
10.
Sjoland H., Eitzman DT, Gordon D., Westrick R., Nabel EG, Ginsburg D.Atherosclerosis progression in LDL receptor deficient and apolipoprotein E-deficient mice is independent of genetic alterations in plasminogen activator inhibitor-1 . Arterioscler Thromb Vasc Biol2000; 20: 846-52.
11.
Saksela O., Rifkin DBCell-associated plasminogen activation: regulation and physiological functions . Annu Rev Cell Biol1988; 4:93-126.
12.
Lupu F., Heim DA, Bachmann F., Hurni M., Kakkar VV, Kruithof EKPlasminogen activator expression in human atherosclerotic lesions . Arterioscler Thromb Vasc Biol1995; 15(9):1444-55.
13.
Kinlay S., Selwyn AP, Libby P., Ganz P.Inflammation, the endothelium, and the acute coronary syndromes. J Cardiovasc Pharmacol1998; 32 Suppl 3:S62-S66.
14.
Collen D.On the regulation and control of fibrinolysis. Edward Kowalski Memorial Lecture . Thromb Haemost1980; 43:77-89.
15.
Schneiderman J., Sawdey MS, Keeton MR et al. Increased type-1 plasminogen activator inhibitor gene expression in atherosclerotic plaques of human arteries. Proc Natl Acad Sci USA192; 89:6998-7002.
16.
Kerins DM, Hao O., Vaughan DEAngiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest1995; 96:2515-20.
17.
Ridker PM, Gaboury CL, Conlin PR, Seely EW,Williams GH, Vaughan DEStimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin- angiotensin system and fibrinolytic function. Circulation1993 ; 87(6):1969-73.
18.
Vaughan DE, Lazos S.,Tong K.Angiotensin II regulates the expression of plasminogen activator inhibitor-type1 in cultured endothelial cells.A potential link between the renin-angiotensin system and thrombosis. J Clin Invest1995; 95(3):995-1001.
19.
Juhan-Vague I., Pyke SDM, Alessi MC, Jespersen J., Haverkate F., Thompson SGFibrinolytic factors and risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation1996; 94(9):2057-63.
20.
Brown NJ, Agirbasli MA, Williams GH, Litchfield WR, Vaughan DEEffect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. Hypertension1998; 32(6):965-71.
21.
Matsubara Y. , Hayakawa T., Tsuda T. et al. Angiotensin converting enzyme insertion/deletion polymorphism is associated with plasma antigen levels of plasminogen activator inhibitor-1 in healthy Japanese population . Blood Coagul Fibrinolysis2000;11(2):115-20.
22.
Brown NJ, Ryder D., Gainer JV, Morrow JD, Nadeau J.Differential effects of Angiotensin Converting Enzyme inhibitors on the vasopressor and prostacyclin responses to bradykinin. J Pharmacol Exp Ther1996; 279:703-12.
23.
van Leeuwen RT, Kol A.,Andreotti F., Kluft C., MaseriA, Sperti G.Angiotensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells . Circulation1994; 90(1):362-8.
24.
Brown NJ, Nadeau J., Vaughan DESelective stimulation of tissue-type plasminogen activator (t-PA) in vivo by infusion of bradykinin. Thromb Haemost1997; 77(3):522-5.
25.
Alessi MC, Juhan-Vague I., KooistraT, Declerck PJ, Collen D.Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular line Hep G2. Thromb Haemost1988; 60:491-4.
26.
Vuorinen-Markkola H., Yki-Jarvinen H.Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus. Metabolism1995; 44(1):85-9.
27.
Zannad F., Bray-Desboscs L., el Ghawi R., Donner M.,Thibout E., Stoltz JFEffects of lisinopril and hydrochlorothiazide on platelet function and blood rheology in essential hypertension: a randomly allocated double-blind study . J Hypertens1993; 11(5):559-64.
28.
Erdem Y., Usalan C., Haznedaroglu IC et al. Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension. Am J Hypertens1999; 12(11 Pt 1):1071-76.
29.
Stanziola L. , Greene LJ, Santos RAS.Effect of chronic angiotensin converting enzyme inhibition on angiotensin I and bradykinin metabolism in rats. Am J Hypertens1999; 12(10 Pt 1):1021-29.
30.
Margaglione M., Cappucci G., d'Addedda M et al. PAI-1 plasma levels in a general population without clinical evidence of atherosclerosis: relation to environmental and genetic determinants .ArteriosclerThromb Vasc Biol1998; 18(4):562-7.
31.
Kim DK, Kim JW, Kim S. et al. Polymorphism of angiotensin converting enzyme gene is associated with circulating levels of plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol1997; 17(11):3242-7.
32.
Goodfield NER , Newby DE, Ludlam CA, Flapan ADEffects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure . Circulation1999; 99:2983-5.
33.
Katoh M., Egashira K., Mitsui T., Takeshita A., Narita H.Differential effects of imidapril and candesartan cilexetil on plasminogen activator inhibitor-1 expression induced by prolonged inhibition of nitric oxide synthesis in rat hearts. J Cardiovasc Pharmacol2000; 35(6):932-6.
34.
Seljeflot I. , Moan A., Kjeldsen S., Sandvik E., Arnesen H.Effect of angiotensin II receptor blockade on fibrinolysis during hyperinsulinemia in patients with essential hypertension . Hypertension1996 ; 27: 1299-304.
35.
Mugellini, A.,Zoppi, A., Corradi L. et al. Effect of trandolapril and losartan on plasma PAI-1 and fibrinogen in hypertensive postmenopausal women. Am J Hypertens1998; 11: 11A. (Abstract)
36.
Brown NJ,Agirbasli M., Vaughan DEComparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans. Hypertension1999; 34(2):285-90.
37.
The effect of antihypertensive drug treatment on mortality in the presence of resting electrocardiographic abnormalities at baseline: the HDFP experience.The Hypertension Detection and Follow-up Program Cooperative Research Group. Circulation1984; 70(6):996-1003.
38.
Baseline rest electrocardiographic abnormalities, antihypertensive treatment, and mortality in the Multiple Risk Factor Intervention Trial.Multiple Risk Factor Intervention Trial Research Group. Am J Cardiol1985; 55(1):1-15.
